Sign in

    Shawn

    Managing Director and Senior Analyst at Citigroup

    Shawn Farrell is a Managing Director and Senior Analyst at Citigroup, specializing in equity research with a focus on the communications and networking equipment sector. He provides coverage on key companies including Cisco Systems, Juniper Networks, Arista Networks, and Ciena, with a strong track record reflected by a TipRanks success rate above 60% and average returns exceeding 8% per rating. Shawn began his finance career in the early 2000s, previously holding roles as a senior analyst at Deutsche Bank and Leerink Partners before joining Citigroup in 2018. He holds FINRA Series 7, 63, 86, and 87 registrations and is recognized for his insightful sector analysis and accurate investment recommendations.

    Shawn's questions to Voyager Therapeutics (VYGR) leadership

    Shawn's questions to Voyager Therapeutics (VYGR) leadership • Q2 2024

    Question

    Shawn from Citigroup asked about the competitive positioning of Voyager's anti-tau therapy relative to Biogen's program and the key remaining steps before the SOD1 silencing gene therapy IND filing.

    Answer

    CEO Dr. Al Sandrock differentiated Voyager's C-terminal targeting antibody from Biogen's discontinued N-terminal antibody and positioned its tau-silencing gene therapy as a one-time IV alternative to Biogen's intrathecal ASO, BIIB080. CMO Dr. Toby Ferguson identified the ongoing GLP toxicology studies as the main gating item for the SOD1 program's IND submission.

    Ask Fintool Equity Research AI